Browse by author
Lookup NU author(s): Professor Rakesh Heer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Tissue-preserving focal therapies, such as brachytherapy, cryotherapy, high-intensity focused ultrasound and photodynamic therapy, aim to target individual cancer lesions rather than the whole prostate. These treatments have emerged as potential interventions for localized prostate cancer to reduce treatment-related adverse-effects associated with whole-gland treatments, such as radical prostatectomy and radiotherapy. In this article, the Prostate Cancer RCT Consensus Group propose that a novel cohort-embedded randomized controlled trial (RCT) would provide a means to study men with clinically significant localized disease, which we defined on the basis of PSA level (<= 15 ng/ml or <= 20 ng/ml), Gleason grade (Gleason pattern <= 4+4 or <= 4+3) and stage (<= cT2cNOMO). This RCT should recruit men who stand to benefit from treatment, with the control arm being whole-gland surgery or radiotherapy. Composite outcomes measuring rates of local and systemic salvage therapies at 3-5 years might best constitute the basis of the primary outcome on which to change practice.
Author(s): Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M, Prostate Cancer RCT Consensus Group
Publication type: Article
Publication status: Published
Journal: Nature Reviews Clinical Oncology
Print publication date: 01/08/2014
Online publication date: 22/04/2014
ISSN (print): 1759-4774
ISSN (electronic): 1759-4782
Publisher: Nature Publishing Group
Altmetrics provided by Altmetric